
1 / 2GLP Peptides · Popular Peptides
$130.00$52.00Save 60%
Quantity
$130.00$52.00
Eloralintide — often shortened to Elora in research communities and catalogued as LY3841136 — is a long-acting selective amylin receptor agonist that originated as an investigational compound and appears in published literature on amylin receptor pharmacology, satiety signaling, gastric emptying, and glycemic regulation. Unlike dual-acting amylin analogues, it is characterized by selectivity for amylin receptor complexes, a profile of active research interest in metabolic science. It is offered here strictly as a laboratory reagent for in-vitro and preclinical study.
Real Peptides supplies Eloralintide as 5mg and 10mg multi-dose vials of lyophilized material, finished in the USA. Every batch is tested by an independent analytical laboratory, and the certificate for the current lot is published on the lab results page so it can be reviewed before purchase. Orders ship from facilities in Florida and California within 24 hours. Sold for research use only, not for human or veterinary use.
Eloralintide · 5mg
$52.00$130.00
Recommended with this order
Frequently paired with this compound by other researchers.
For Research Use Only. Not for human consumption or therapeutic treatment.
Multi Dose | Finished in the USA
Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist. It appears in published literature examining satiety signaling, gastric emptying, and glycemic regulation in preclinical models.
Supplied as a lyophilized research reagent in 5mg and 10mg multi-dose vials. HPLC-verified to ≥99% purity.
For Research Use Only. Not for human or veterinary use.

Eloralintide is a long-acting, selective amylin receptor agonist developed by Eli Lilly under the code LY3841136. Native amylin is a hormone co-secreted with insulin by pancreatic beta cells; in preclinical models it slows gastric emptying, engages hindbrain satiety circuits, and participates in post-meal glucose regulation. Eloralintide was engineered to mimic this signaling with an extended duration of action.
Its selectivity is what distinguishes it in the amylin class: published pharmacology characterizes it as selective for amylin receptor complexes rather than acting as a dual amylin-calcitonin receptor agonist, a receptor profile that has made it a compound of significant research interest.
Real Peptides supplies Eloralintide as a laboratory research reagent. It is not a drug, is not approved for any therapeutic use, and is not for human or veterinary administration.

Eloralintide appears in a growing body of published literature spanning receptor pharmacology, satiety and energy-balance signaling, gastric emptying, and glycemic regulation. Peer-reviewed results from its originator’s Phase 2 clinical program were published in The Lancet and presented at ObesityWeek 2025, and Phase 3 studies are ongoing, alongside separate published work examining co-administration with incretin receptor agonists.
For laboratory settings, this makes Eloralintide a well-documented reference compound for studying selective amylin receptor activation in vitro and in preclinical models, with an unusually deep published record for a compound of its generation.
All such findings are reported here as research context only; nothing on this page is a claim about therapeutic use of the material supplied.

Within the amylin class, Eloralintide’s defining feature is receptor selectivity. Compounds such as cagrilintide act on both amylin and calcitonin receptors, while published pharmacology characterizes Eloralintide as a selective amylin receptor agonist — a cleaner probe for isolating amylin-specific signaling in research designs.
Each lot supplied by Real Peptides is finished in the USA, verified by an independent analytical laboratory, and shipped from US facilities with the current lot’s certificate of analysis published for review before purchase.
GLP Peptides compounds
Research library